A startup developing artificial intelligence technology for drug discovery is partnering with a large German drugmaker in connection with its most recent investment round. Salt Lake City-based ...

Some new investors pitched in to Recursion Pharmaceuticals Inc.'s $121 million series C financing, adding to the industry's vision of the importance of AI and machine learning. The round was led by ...

When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. The opportunity to explore a multi-genre universe in innovative ways is extremely exciting. Matt ...

Recursion's stock has been consistently rated as "Hold" by this analyst due to skepticism about its AI-driven drug discovery approach and its financial instability. The company's IPO raised over $500 ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

SALT LAKE CITY--(BUSINESS WIRE)--Recursion Pharmaceuticals today announced the close of an additional $2.15M in funding, bringing its Series A round to a total of $15.05M for drug discovery at the ...

SALT LAKE CITY--(BUSINESS WIRE)--Recursion, a next-gen biopharma company combining automated, experimental biology with artificial intelligence to discover and develop drugs at scale, today announced ...